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Thecytotoxiccompoundhydroxyurea(HU)iseﬀectivetherapyforsicklecelldisease.However,itseﬀectonunsaturatedmembrane
lipids is unknown. Red cell fatty acids were investigated in HU-treated (n = 19) and HU-untreated (n = 17) sickle cell patients
and controls (n = 20). The HU-treated compared with the HU-untreated patients had lower arachidonic (AA) acid level in
ethanolamine,physphoglycerids(EPG)(22.9±1.2v e r s u s2 4 .0±1.1%, P<0.05)serineSPG(22.13±2.2v e r s u s2 4 .9±2.3%, P<
0.01) phosphoglycerides. The treated patients and controls had comparable levels of docosahexaenoic (DHA) and total n-3 fatty
acids in EPG and choline phosphoglycerides (CPG). In contrast, the untreated group had signiﬁcantly (P<0.05) lower DHA and
total n-3 compared with the controls in EPG (2.7 ± 0.4v e r s u s3 .2 ± 0.6% and 4.6 ± 0.5v e r s u s5 .2 ± 0.7%) and CPG (0.7 ±
0.2v e r s u s1 .0 ± 0.2% and 1.2 ± 0.2v e r s u s1 .4 ± 0.3). HU is known to activate cytosolic phospholipase A2 and cyclooxygenase
2, and from this study, it appears to induce mobilisation of AA from the inner cell membrane EPG and SPG. Hence, eicosanoids
generated from the released AA may play a role in clinical improvements which occur in HU-treated patients.
1.Introduction
Hydroxyurea (HU) is eﬀective therapy for adults, children
and infants with severe sickle cell disease [1–4]. It is thought
to reduce the frequency of painful crises by induction
of foetal haemoglobin (HbF) and subsequent inhibition
of polymerisation of deoxyhaemoglobin S [5]. However,
clinical improvements do occur prior to a signiﬁcant rise in
levels of HbF [6]. This suggests that HU may modulate the
pathophysiology of the disease by other additional factors.
HU has been shown to increase red blood cell (RBC)
deformability [7], decrease the expression of adhesion mol-
ecules on reticulocytes [8], and reduce the translocation of
phosphatidylserine from inner to outer leaﬂet of RBC
membrane lipid bilayer [9]. Adhesion, aggregation, and de-
formability of blood cells are strongly modulated by mem-
brane fatty acids [10–12]. Steady-state sickle cell patients
not treated with HU have abnormal RBC, platelets and
mononuclear cell fatty acids, which is characterised by an
increase in arachidonic acid (AA, 20:4n-6) and a decrease
in linoleic acid (LA, 18:2n-6), eicosapentaenoic acid (EPA,
20:5n-3), and docosahexaenoic acid (DHA, 22:6n-3) [13–
15]. These ﬁndings have led to the postulation that “an
imbalance of blood cell membrane n-3 and n-6 fatty acids
may be the antecedent of loss of membrane asymmetry,
blood cell adhesion, aggregation and, vasoocclusion in SCD’’
[16]. The aim of this study was to elucidate whether HU
treatment modulates RBC membrane fatty acids of steady-
state homozygous sickle cell patients (HbSS).2 Journal of Lipids
2.SubjectandMethods
2.1. Subjects. Steady-state HbSS sickle cell patients, treated
(age 7–26; n = 19) and untreated (age 7–22; n = 17) with
HU, and healthy (HbAA) controls (age 6–21; n = 20)
matched for ethnicity and economic background were
enrolled from the Abnaof Paediatric Hospital, Khartoum,
Sudan. The phenotypic characteristic was conﬁrmed by
cellulose acetate electrophoresis. The treated patients were
on HU for three months or longer. The exclusion criteria
were sickle cell crisis, acute illness in the previous month,
presence of other chronic diseases, blood transfusion in the
previous four months, or pregnancy. The Research Board
of the Faculty of Medicine, University of Khartoum, Sudan,
approved the study. Self- or investigator-read and explained
written consent was obtained from the participants or their
guardians. In addition, approval was obtained from the
National Research Ethics Service, Southampton & South
West Hampshire Research Ethics Committee (A) UK (REC
reference: 05/Q1702/48).
After an overnight fast, 5mL of whole blood was taken
from the patients and controls in EDTA tubes. The whole
blood was fractionated into RBC and plasma by cold
centrifugation at 3000rpm for 15min. The top plasma layer
was carefully siphoned oﬀ and transferred into another tube.
The lower red cell layer was washed twice with physiological
saline (0.85% NaCl) and centrifuged to remove traces of
plasma and buﬀy coat. The resulting plasma and RBC pellet
were stored at −80◦C until analysis.
2.2. Analysis of Plasma Lipids. Plasma total cholesterol,
high-density lipoprotein cholesterol (HDL-cholesterol), and
triglyceride concentrations were analysed by the use of the
Ace Alera Clinical Chemistry System (Alfa Wassermann
Diagnostic Technologies B.V. Pompmolenlaan 24, 3447 GK
Woerden,TheNetherlands).Low-densitylipoproteincholes-
terol (LDL-cholesterol) was computed with the following
equation: {LDL-Cholesterol = Total Cholesterol – (HDL-
Cholesterol + Triglyceride/5)}.
2.3. Analysis of Red Blood Cell Fatty Acids. Total lipids were
extracted by the method of Folch et al. [17] by homogenising
0.5mL of RBC in 2:1 v/v chloroform/methanol containing
0.01% (w/v) butylated hydroxytoluene, under nitrogen.
The major phospholipid classes were separated by thin-
layer chromatography on silica gel plates with the use of
the developing solvents: chloroform/methanol/methylamine
(65:35:15 v/v/v). The resulting bands were visualised by
spraying the plate with 0.01% (w/v) methanolic 2, 7-
dichloroﬂuorescein and identiﬁed by authentic standards
developed on the same plates.
Fatty acid methyl esters (FAMEs) were prepared by heat-
ingthephospholipidbandsin4mLof15%methanolicacetyl
chloride in a sealed vial at 70◦C for 3 hours, under nitrogen.
The resulting FAMEs were extracted with petroleum spirit,
dried, dissolved in heptane, and subsequently separated by
a gas chromatograph (HRGC MEGA 2 series, Fisons Instru-
ments, Italy) ﬁtted with a BP 20 capillary column (50m ×
0.32mmID,0.25:ﬁlm).Hydrogenwasusedasacarriergasat
2mL/min, and the injector, oven, and detector temperatures
were 250, 230, and 280◦C, respectively.
Quality-certiﬁedfattyacidmethylesterstandardmixture
(Supelco 37 Component FAME Mix. U47885-U, Sigma-
Aldrich, Dorset, UK) and GC-MS-authenticated fatty acid
methyl esters prepared from lipid extract of vegetable seed
oils, which contain alpha-linolenic, gamma-linolenic, and
stearidonic acids, and from bovine brain L-A-phosphati-
dylethanolamine Type 1 (Sigma-Aldrich, Dorset, UK) were
used to identify the fatty acids. Peak areas were computed
with EZChrom chromatography data system (Scientiﬁc Soft-
ware, Inc, San Ramon, Calif, USA).
2.4. Statistical Analysis. The data are expressed as mean ±
SD. Unpaired t-test was used to explore diﬀerences in
concentrations of total, HDL, and LDL cholesterol and
triglycerides between the HU-treated patients and healthy
controls. RBC fatty acids of the HU-treated and untreated
patients and healthy controls were compared with one-
way ANOVA and the post hoc test for unequal variance,
Tamhane’s T2. Statistical signiﬁcance was assumed at a “P”
value of less than 0.05. The statistical software SPSS for
Windows, Version 17 (SPSS Ltd., Woking, Surrey, UK) was
used to analyse the data.
3. Results
3.1. Plasma Lipids. Mean concentrations of total, HDL, and
LDL cholesterol and triglyceride of the HU-treated sickle
cell patients and healthy controls are presented in Table 2.
The patients, compared with their healthy counterparts, had
lower total HDL (P<0.001) and LDL (P<0.01) cholesterol.
3.2. Red Blood Cell Fatty Acids. Percent fatty acid com-
position of RBC choline phosphoglycerides (CPG) and
sphingomyelin (SPM), the major phospholipids of the
outermembraneleaﬂet,andethanolaminephosphoglyceride
(EPG) and serine (SPG) phosphoglycerides, the dominant
phospholipids of the inner membrane leaﬂet, are shown in
Tables 3, 4, 5,a n d6,r e s p e c t i v e l y .
3.2.1. Red Cell CPG. The healthy controls had lower levels of
palmitic acid (C16:0), oleic acid (C18:1n-9), total monoenes
and adrenic acid (C22:4n-6) (P<0.001) and higher
stearic (C18:0) and linoleic (C18:2n-6) acids and total
n-6 (P<0.001) fatty acids compared with the HU-
treated and untreated patients. In addition, they had higher
docosahexaenoic acid (22:6n-3), n-3 metabolites (P<0.01)
and total n-3 fatty acids (P<0.05) than the HU-untreated
patients. Stearic and gamma linolenic (18:3n-6, GLA) acids
(P<0.001) and total saturated fatty acids (P<0.01) were
reduced in the HU-untreated compared with the treated
patients.
3.2.2. Red Cell SPM. Palmitic, stearic and arachidonic acids
and total saturates were elevated (P<0.01), and oleic
and nervonic (P<0.01) and total monoenes (P<0.001)Journal of Lipids 3
Table 1: Characteristics of the HU-treated and untreated HbSS patients and healthy (HbAA) subjects.
Characteristics HU-treated HbSS HU-untreated HbSS Healthy control (HbAA)
Number of subjects 19 17 20
Gender (Male/Female) 8/11 7/10 9/11
Age ± SD (year) 14.5 ± 4.3 14.5 ± 6.1 9.7 ± 6.7
Weight ± SD (kg) 36 ± 7.1 31.5 ± 11.8 36.1 ± 14.6
Height ± SD (cm) 146.9 ± 15.3 127.8 ± 25.5 146.3 ± 15.0
Table 2: Plasma lipid concentrations of steady state HU treated HbSS sickle cell patients and HbAA healthy controls.
Plasma lipids HbAA (n = 20) HbSS (n = 17)
LDL-cholesterol (mmol/L) 2.4 ± 0.5 1.7 ± 0.7∗∗
HDL-cholesterol (mmol/L) 1.1 ± 0.3 0.8 ± 0.2∗∗∗
Total cholesterol (mmol/L) 3.71 ± 0.56 2.7 ± 0.8∗∗∗
Triacylglycerol (mmol/L) 1.01 ± 0.4 1.24 ± 0.03
HbSS patients versus HbAA controls: ∗∗P<0.01, ∗∗∗P<0.001;
Table 3: Fatty acid composition of red blood cell choline phosphoglycerides of HU-untreated (n = 17) and treated (n = 19) HbSS patients
and HbAA controls (n = 20).
Fatty acids HbSS (untreated) HbSS (treated) HbAA (healthy control)
16:0 (Palmitic acid) 36.7 ± 1.6 36.3 ± 1.7××× 31.8 ± 2.5+++
18:0 (Stearic acid) 8.9 ± 0.7∗∗∗ 10.3 ± 1.2××× 13.2 ± 1.0+++
20:0 (Arachidic acid) 0.1 ± 0.03∗∗∗ 0.2 ± 0.1× 0.1 ± 0.1
22:0 (Behenic acid) tr. tr. tr.
24:0 (Lignoceric acid) 0.04 ± 0.01 0.05 ± 0.01 .04 ± 0.01

saturates 46.0 ± 1.3∗∗ 47.2 ± 0.8×× 45.2 ± 1.9
16:1n-7 (Palmitoleic acid) 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
18:1n-7 (Vaccenic acid) 1.6 ± 0.2 1.7 ± 0.3× 1.4 ± 0.2+
18:1n-9 (Oleic acid) 18.3 ± 1.1 17.7 ± 1.5××× 14.2 ± 1.5+++
24:1n-9 (Nervonic acid) tr. tr. tr.

monoenes 20.2 ± 1.1 19.7 ± 1.6××× 15.9 ± 1.6+++
18:2n-6 (Linoleic acid) 16.3 ± 1.4 15.4 ± 2.6××× 20.7 ± 2.1+++
18:3n-6 (γ-linolenic acid) 0.1 ± 0.02∗∗∗ 0.1 ± 0.03 0.1 ± 0.05
20:2n-6 (Eicosadienoic acid) 0.5 ± 0.1 0.4 ± 0.2 0.5 ± 0.1
20:3n-6 (Dihomo-γ-linolenic) 1.9 ± 0.4 1.7 ± 0.2×× 2.1 ± 0.1
20:4n-6 (Arachidonic acid) 9.6 ± 0.7 9.5 ± 1.1 9.4 ± 1.5
22:4n-6 (Adrenic acid) 0.9 ± 0.2 0.9 ± 0.2××× 0.7 ± 0.1+++
22:5n-6 (Osbond acid) 0.5 ± 0.1 0.5 ± 0.1× 0.6 ± 0.2+

metabolites 13.6 ± 0.7 13.1 ± 1.3 13.4 ± 1.7

n-6 29.9 ± 1.6 28.4 ± 1.9××× 34.1 ± 2.7
18:3n-3 (α-Linolenic acid) tr. tr. tr.
20:5n-3 (Timnodonic acid) 0.1 ± 0.02 0.1 ± 0.05 0.11 ± 0.03
22:5n-3 (Clupanodonic acid) 0.3 ± 0.06 0.3 ± 0.07 0.3 ± 0.05
22:6n-3 (Cervonic acid) 0.7 ± 0.2 0.8 ± 0.4 1.0 ± 0.2++

metabolites 1.1 ± 0.2 1.2 ± 0.4 1.3 ± 0.3++

n-3 1.2 ± 0.2 1.2 ± 0.4 1.4 ± 0.3+
N6/N3 26.58 ± 5.03 24.91 ± 6.78 25.65 ± 5.09
tr.: trace.
HU-untreated versus treated HbSS patients, ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001.
HU-untreated HbSS patients versus HbAA healthy controls, +P<0.05, ++P<0.01, +++P<0.001.
HU-treated HbSS patients versus HbAA healthy controls, ×P<0.05, ××P<0.01, ×××P<0.001.4 Journal of Lipids
Table 4: Fatty acid composition of red blood cell sphingomyelin of HU-untreated (n = 17) and treated (n = 19) HbSS patients and HbAA
healthy controls (n = 20).
Fatty acids HbSS (untreated) HbSS (treated) HbAA (healthy control)
16:0 21.1 ± 4.3∗ 25.3 ± 3.5 26.1 ± 2.2++
18:0 8.7 ± 2.2∗ 11.9 ± 3.5 11.3 ± 2.0++
20:0 2.0 ± 0.2 1.00 ± 0.2××× 1.44 ± 0.2+++
22:0 8.1 ± 1.5∗ 6.6 ± 1.3 7.6 ± 1.1
24:0 25.3 ± 4.8∗∗∗ 18.5 ± 2.9×× 21.6 ± 2.6+

saturates 63.9 ± 3.8 63.8 ± 3.1××× 68.2 ± 1.4++
16:1n-7 tr. tr. tr.
18:1n-7 0.3 ± 0.1∗∗∗ 0.7 ± 0.1×× 0.5 ± 0.1+++
18:1n-9 3.8 ± 1.9 3.4 ± 0.6××× 2.0 ± 0.3++
24:1n-9 17.8 ± 3.6∗∗ 14.2 ± 1.7 13.9 ± 1.7++

monoenes 21.9 ± 2.8∗∗∗ 18.3 ± 2.0× 16.5 ± 1.8+++
18:2n-6 2.1 ± 1.1 2.3 ± 0.6 2.0 ± 0.3
18:3n-6 tr. tr. tr.
20:2n-6 0.4 ± 0.3∗∗ 0.1 ± 0.04×× 0.09 ± 0.04++
20:3n-6 0.3 ± 0.1∗∗ 0.5 ± 0.1×× 0.3 ± 0.1
20:4n-6 3.7 ± 1.3∗ 4.9 ± 15 . 1 ± 1.3++
22:4n-6 1.8 ± 1.0 2.0 ± 0.8× 1.3 ± 0.4
22:5n-6 1.4 ± 0.6 1.3 ± 0.6 1.1 ± 0.3

metabolites 7.5 ± 2.9 8.4 ± 1.9 7.9 ± 2.1

n-6 9.6 ± 3.5 10.8 ± 1.7 9.9 ± 2.2
18:3n-3 tr. tr. tr.
20:5n-3 0.11 ± 0.02∗∗∗ 0.07 ± 0.02 0.06 ± 0.02+++
22:5n-3 0.4 ± 0.2 0.45 ± 0.2 0.4 ± 0.1
22:6n-3 1.4 ± 0.7 1.8 ± 0.8 1.7 ± 0.6

metabolites 1.9 ± 0.8 2.4 ± 0.9 2.1 ± 0.7

n-3 1.9 ± 0.8 2.4 ± 0.9 2.1 ± 0.7
N6/N3 5.3 ± 1.6 5.3 ± 1.7 4.9 ± 1.1
tr.: trace.
HU-untreated versus treated HbSS patients: ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001.
HU-untreated HbSS patients versus HbAA healthy controls: +P<0.05, ++P<0.01, +++P<0.001.
HU-treated HbSS patients versus HbAA healthy controls: ×P<0.05, ××P<0.01, ×××P<0.001.
were more reduced in the healthy controls than in the
HU-untreated patients. The HU-treated compared with
the untreated patients had increased palmitic, stearic, and
arachidonic acids (P<0.05) and decreased lignoceric acid
(C24:0) total monoenes (P<0.001), and nervonic acid
(P<0.01).
3.2.3. Red Cell EPG. The healthy control group compared
with the HU-treated and untreated patients had reduced
stearic, total saturates, adrenic and dihomo gamma linolenic
(20:3n-6, DHGLA) (P<0.001) and increased linoleic and
eicosapentaenoic (20:5n-3) acids (P<0.001). The HU-
treated patients had lower arachidonic, adrenic, osbond
(22:5n-6) (P<0.05), and n-6 metabolites and total n-6
(P<0.001) than their untreated counterparts.
3.2.4. Red Cell SPG. Both the HU-treated and untreated
patients had lower linoleic (P<0.001) and higher DHGLA,
adrenic acid, osbond acid and total n-6 (P<0.01) compared
with the healthy control subjects. The HU-treated patients
had lower GLA, eicosadienoic (20:2n-6), arachidonic acids,
and osbond acid, n-6 metabolites and total n-6 (P<0.01)
than their untreated counterparts.
4. Discussion
The reduced concentrations of total, HDL, and LDL choles-
terol in the HU-treated sickle cell patients are consistent with
the low level of HDL, LDL [18–22], and total cholesterol [23]
reported in HU-untreated steady-state sickle cell patients.
Thepatientsandhealthycontrolsubjectsinthecurrentstudy
w e r eb r o a d l ym a t c h e df o ra g e ,g e n d e r( T a b l e1), ethnicity,
and socioeconomic background. Consequently, the observed
reduction in cholesterol levels in the HU-treated patients
was unlikely to have been a reﬂection of genetic or envi-
ronment factors. It has been postulated hypocholesterolemia
in sickle cell patients is due to haemodilution, down
regulation of cholesterol synthesis, and decreased transfer
of cholesterol from membrane to circulating high-densityJournal of Lipids 5
Table 5: Fatty acid composition of red blood cell ethanolamine phosphoglycerides of HU-untreated (n = 17) and treated (n = 19) HbSS
sickle cell patients and HbAA healthy controls (n = 20).
Fatty acids HbSS (untreated) HbSS (treated) HbAA (healthy control)
16:0 12.8 ± 1.3 12.8 ± 1.3 12.8 ± 1.2
18:0 7.9 ± 0.9 8.7 ± 1.4××× 6.0 ± 0.7+++
20:0 0.1 ± 0.02 0.08 ± 0.03 0.06 ± 0.03
22:0 0.03 ± 0.01∗∗∗ 0.07 ± 0.02 0.08 ± 0.04+++
24:0 0.06 ± 0.03∗ 0.08 ± 0.02××× 0.06 ± 0.02

saturates 21.02 ± 1.0 21.9 ± 1.5××× 19.1 ± 1.1+++
16:1n-7 0.1 ± 0.03∗∗∗ 0.1 ± 0.02 0.1 ± 0.04+++
18:1n-7 0.9 ± 0.2 1.2 ± 0.8 0.9 ± 0.1
18:1n-9 13.1 ± 1.2 12.1 ± 1.1 12.9 ± 0.7
24:1n-9 tr. tr. tr.

monoenes 14.0 ± 1.3 13.2 ± 1.1 13.9 ± 1.0
18:2n-6 4.9 ± 0.7 4.9 ± 0.9××× 6.7 ± 0.9+++
18:3n-6 0.2 ± 0.05∗∗∗ 0.04 ± 0.01 0.04 ± 0.01+++
20:2n-6 0.6 ± 0.2 0.5 ± 0.1 0.5 ± 0.1
20:3n-6 1.4 ± 0.3 1.3 ± 0.2××× 1.0 ± 0.1+++
20:4n-6 24.0 ± 1.1∗ 22.9 ± 1.2×× 24.8 ± 1.5
22:4n-6 10.8 ± 0.1∗ 9.89 ± 1.0××× 8.6 ± 0.7+++
22:5n-6 2.6 ± 0.4∗ 2.2 ± 0.5 1.9 ± 0.3+++

metabolites 39.4 ± 1.3∗∗∗ 36.8 ± 2.2 36.8 ± 1.7+++

n-6 44.3 ± 1.5∗∗∗ 41.4 ± 2.5× 43.9 ± 1.8
18:3n-3 0.08 ± 0.04 0.08 ± 0.02 0.1 ± 0.03
20:5n-3 0.11 ± 0.03∗ 0.15 ± 0.05××× 0.23 ± 0.06+++
22:5n-3 1.7 ± 0.3 1.6 ± 0.3 1.7 ± 0.2
22:6n-3 2.7 ± 0.4 2.9 ± 0.88 3.2 ± 0.6+

metabolites 4.5 ± 0.5 4.6 ± 1.1 5.1 ± 0.7+

n-3 4.6 ± 0.5 4.7 ± 1.1 5.2 ± 0.7+
N6/N3 9.8 ± 1.4 9.3 ± 2.34 8.5 ± 1.3+
tr.: trace.
HU-untreated versus treated HbSS patients: ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001.
HU-untreated HbSS patients versus HbAA healthy controls: +P<0.05, ++P<0.01, +++P<0.001.
HU-treated versus HbAA healthy controls: ×P<0.05, ××P<0.01, ×××P<0.001.
lipoprotein (HDL) because of reduced activity of lecithin-
cholesterol acyltransferase [23, 24]. In the current study,
the HU patients and healthy controls had a comparable
level of triacylglycerols. Hence, the hypocholesterolemia in
the patients could not be explained by haemodilution.
Likewise, downregulation of biosynthesis of cholesterol may
not be a factor as there is evidence that RBCs of sickle cell
patients have higher content of cholesterol [25, 26]. SCD
patients have lower level of apolipoprotein A-I [25, 27, 28],
and deoxygenated HbS red cells have been shown to have
increased uptake of cholesterol analogue [29]. Hence, it is
plausible; the hypocholesterolemia observed in the patients
was a reﬂection of increased uptake by RBC membranes and
reduced transfer to circulating HDL.
The current comparative study of Sudanese homozygous
sickle cell patients and healthy controls revealed both HU-
treated and untreated patients had abnormal red cell fatty
acidpattern,whichwasmorepronouncedinthelattergroup.
The remarkable anomalies in the HU-untreated patients
compared with the healthy controls were decreased linoleic
and stearic and increased palmitic and oleic acids in CPG,
decreased palmitic and stearic and increased nervonic and
lignoceric acids in SPM, decreased linoleic acid, EPA, and
DHAandincreasedstearic,adrenic,andosbondacidsinEPG
and decreased linoleic and oleic and increased adrenic and
osbond acids. These ﬁndings are broadly consistent with the
previous ﬁndings in serum phospholipids [30], red cell total
phospholipids [31], red cell phospholipid classes [13, 15],
andtotallipidsofmononuclearcellsandplatelets[16].These
ﬁndings in steady-state homozygous sickle cell patients of
diﬀerent ethnic, cultural, and socioeconomic backgrounds
demonstrate the disease induces blood cell membrane fatty
acid perturbation. This could be due to (a) metabolic
dysfunction-impaired synthesis, uptake, and/or enhanced
turnover; (b) peroxidation caused by iron overload. Both the
HU-untreatedpatientsandhealthycontrolshadverylown-3
fatty acids compared with the British and Nigerian subjects
previously investigated by our group [15]. This diﬀerence
is most likely a reﬂection of the n-3 fatty acid status of the
populations studied since we have observed North Sudanese6 Journal of Lipids
Table 6: Fatty acid composition of red blood cell serine phosphoglycerides of HU-untreated (n = 17) and treated (n = 19) HbSS sickle cell
patients and HbAA healthy controls (n = 20).
Fatty acids HbSS (untreated) HbSS (treated) HbAA (healthy control)
16:0 4.4 ± 0.9 5.5 ± 1.6 5.2 ± 1.2
18:0 41.9 ± 1.3 42.9 ± 1.9 41.6 ± 1.1
20:0 0.3 ± 0.1 0.3 ± 0.06×× 0.2 ± 0.07++
22:0 0.1 ± 0.04∗∗∗ 0.2 ± 0.1 0.2 ± 0.07
24:0 tr. tr. tr.

saturates 46.9 ± 0.9∗∗∗ 49.2 ± 0.8××× 47.5 ± 1.0
16:1n-7 tr. tr. tr.
18:1n-7 0.4 ± 0.9∗∗∗ 0.8 ± 0.2 0.7 ± 0.1+++
18:1n-9 4.9 ± 1.03∗ 6.0 ± 1.23 5.1 ± 1.0
24:1n-9 0.03 ± 0.01∗∗∗ 0.4 ± 0.31 0.3 ± 0.23+++

monoenes 5.4 ± 1.1∗∗ 7.1 ± 1.5×× 5.4 ± 1.2
18:2n-6 3.20 ± 0.6 3.3 ± 0.6××× 6.1 ± 1.6+++
18:3n-6 0.2 ± 0.06∗∗∗ 0.06 ± 0.03××× 0.02 ± 0.02+++
20:2n-6 0.5 ± 0.1∗∗∗ 0.2 ± 0.04 0.3 ± 0.09+++
20:3n-6 3.2 ± 0.8 2.9 ± 0.8××× 2.1 ± 0.3+++
20:4n-6 24.9 ± 2.3∗∗ 22.13 ± 2.2××× 25.7 ± 1.9
22:4n-6 6.7 ± 1.1 6.1 ± 1.0××× 3.9 ± 0.8+++
22:5n-6 3.4 ± 0.7∗∗ 2.7 ± 0.58×× 2.1 ± 0.5+++

metabolites 38.8 ± 1.4∗∗∗ 34.1 ± 1.9 33.9 ± 2.4+++

n-6 42.0 ± 1.2∗∗∗ 37.0 ± 2.0××× 40.1 ± 2.7++
18:3n-3 tr. tr. tr.
20:5n-3 0.07 ± 0.01 0.08 ± 0.09 0.11 ± 0.04++
22:5n-3 1.4 ± 0.3 1.2 ± 0.3 1.1 ± 0.2++
22:6n-3 3.0 ± 0.6 2.8 ± 0.8 2.7 ± 0.8

metabolites 4.4 ± 0.7 4.1 ± 1.0 3.9 ± 1.1

n-3 4.4 ± 0.7 4.1 ± 1.03 3.9 ± 0.1
N6/N3 9.7 ± 1.9 9.7 ± 2.6 11.0 ± 2.9
tr.: trace.
HU-untreated versus treated HbSS patients: ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001.
HU-untreated HbSS patients versus HbAA healthy controls: +P<0.05, ++P<0.01, +++P<0.001.
HU-treated HbSS Patients versus HbAA healthy controls: ×P<0.05, ××P<0.01, ×××P<0.001.
maternal milk [32] and blood (unpublished) have very low
content of these nutrients.
Hydroxyurea had a profound eﬀect on fatty acid com-
position of membrane phospholipids, particularly sphin-
gomyelin, and ethanolamine and serine phosphoglycerides.
The striking eﬀect on the former phospholipid was a reduc-
tion of 18.1, 26.7, and 20.6% of behenic (C20:0), lignoceric
(C22:0), and nervonic (C24:1n-9) acids, respectively. The
HU-induced changes in sphingomyelin composition are
signiﬁcant since lipid rafts, the highly ordered membrane
microdomains, which are thought to play a pivotal role in
membrane traﬃcking, signal transduction, and gene and
protein expression, are rich in sphingomyelin [33, 34].
Moreover, saturated and mono-unsaturated fatty acids are
structuralcomponentsandmajorfunctionaldeterminantsof
sphingomyelin.
In addition, hydroxyurea reduced arachidonic acid (AA,
C20:4n-6) signiﬁcantly in both ethanolamine (−4.7%) and
serine (−11.1%) phosphoglycerides, phospholipids found
predominately in the inner leaﬂet of membrane lipid bilayer.
Such reductions were not apparent in choline phosphoglyc-
erides and sphingomyelin, which are principally found in
the outer leaﬂet of membrane lipid bilayer. Hydroxyurea
generates nitric oxide in vivo [35–37]a n din vitro [38, 39],
and the functionally coupled cPLA2α and cyclooxygenase 2
(COX2) [40] are activated by nitric oxide [41, 42].
Prostaglandin E2 (PGE2), which is a metabolite of AA
and a vasodilator, has been shown to induce the synthesis
of foetal haemoglobin in peripheral blood derived from
erythroid colonies from normal and sickle cell adults [43].
In rats, the HU-induced synthesis of foetal haemoglobin
is obviated by aspirin, the potent inhibitor of COX [44].
Hence, it is tenable to suggest, in the HU-treated patients,
AAisselectivelyreleasedbytheactivationofthearachidonic-
acid-selective cytosolic phospholipase A2α (cPLA2α)a n d
subsequently metabolised by COX2 to generate PGE2.
Consistent with our previous ﬁndings in HU-untreated
HbSS patients [16], the HU-untreated patients in this study
had signiﬁcantly lower levels of DHA and total n-3 fatty
acids in CPG and EPG and of EPA in EPG, SPG, and SPMJournal of Lipids 7
compared with healthy controls. In contrast, in the HU-
treated patients, the reduction in n-3 fatty acids was
restricted only to EPA in EPG. It appears the n-3 fatty
acid abnormality often observed in HU-untreated patients
was partially ameliorated by hydroxyurea treatment. This
modulation of membrane fatty acid composition would be
expected to help enhance transmembrane ion ﬂux, cell
hydration, rheology, and deformability [45–47], factors
which are known to improve in HU-treated sickle cell
patients [7, 48, 49].
This investigation demonstrates, hydroxyurea modulates
red blood cell membrane fatty acid abnormalities including
the n-3/n-6 imbalance reported previously in steady-state
homozygous sickle cell patients. These modulations in
synergywiththeHU-generatedvasodilators,nitricoxideand
PGE2, maybe play a critical role in clinical improvements
whichoccurpriortotheincreasedsynthesisofHbFintreated
patients.
The current study did not investigate the eﬀect of
hydroxyurea on metabolism of eicosanoids derived from
arachidonic acid, oxidative stress, and fatty acid composition
of other blood cells, such as platelets and leukocytes. These
limitations are potential lines of inquiry which may need to
be explored in future studies.
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